Cure8 found this source from cbs17.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the full...

An FDA label update for PYZCHIVA adds/clarifies that this ustekinumab product is indicated for Crohn's disease and ulcerative colitis and reiterates safety monitoring steps (for infections and TB) that matter to people...

The FDA label for XELJANZ/XELJANZ XR (tofacitinib) highlights serious safety risks and monitoring steps relevant to people with ulcerative colitis and other autoimmune conditions who may be using or considering this JAK...

The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...

Cure8 found this source from cbs17.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the full...

The study identifies candidate metabolites that may underlie gut–brain biochemical crosstalk during colitis, which could point to early biomarkers or mechanistic targets relevant to IBD-related brain effects.

The study identifies a cellular mechanism by which arctigenin reduced inflammatory macrophage death and improved colitis in mice, suggesting a potential new target (macrophage FAO → GSDMD) for therapies or...

Endoscopy in this pediatric multicenter series found a high diagnostic yield and confirmed IBD and other treatable conditions; this matters for families and clinicians in resource-limited settings because improving...

A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and...

If true, a common gut microbe (Fusobacterium nucleatum) and its metabolite succinic acid could worsen intestinal inflammation by changing macrophage behavior, suggesting new targets to reduce flares or mucosal injury in...

Algorithms guide how UC is diagnosed and monitored (endoscopy, labs, fecal markers, imaging) and when to escalate to surgery or other interventions; that affects surveillance, treatment choices, and complication...

CMV can complicate acute colitis in people with IBD and may change treatment decisions; knowing which tests are most sensitive or specific helps clinicians decide how to work up suspected CMV colitis during...

This study synthesizes randomized trial evidence about the role of gut microbiota in ulcerative colitis and whether fecal microbiota transplantation (FMT) can help induce remission. People with UC may encounter FMT as a...

The study suggests dietary tryptophan might reduce bacterial-induced acute lung injury in the context of colitis by altering gut–lung immune signaling, which could be relevant to IBD patients who are at risk for...

This study identifies molecular targets and organoid-based effects of ganoderic acid A on inflammatory pathways relevant to IBD, pointing to a potential multi-target avenue for future drug-discovery research.

This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...

This trial is testing duvakitug as a maintenance treatment for people with moderately to severely active ulcerative colitis who responded to an earlier study, which could expand treatment options if later shown to be...

People with IBD often look for safe, low-cost adjuncts to medical therapy. This review compiles mechanisms by which dietary polysaccharides could support gut barrier function, beneficial microbes, and anti-inflammatory...

People with Crohn’s disease facing surgery may have varying risks of complications; better biomarkers and models could help tailor perioperative care and decision-making. The review signals active research toward more...

JAK1 inhibitors are an established therapeutic pathway in IBD; new, more selective small molecules could expand future treatment options. This study reports a novel compound with strong preclinical activity against...

AI tools are being tested to speed capsule endoscopy reading and help triage cases, which matters to people with IBD because capsule endoscopy is commonly used to detect small-bowel ulcers and inflammation.

People with IBD face an elevated lifetime risk of colitis-associated cancer; improved detection and risk prediction could lead to earlier treatment and better outcomes. AI could make surveillance more accurate and...

The work links intestinal inflammation with neurobehavioral changes in a mouse colitis model and suggests certain p‑coumaric acid derivatives can reduce inflammation and anxiety/depression‑like behaviors, which could...

This preclinical study suggests a fermented postbiotic product may protect the colon in a mouse model of ulcerative colitis by altering the microbiome and tryptophan metabolites and by reducing ferroptotic cell death....

The study presents a mitochondria-targeted compound that reduced necrosis markers, HMGB1, and IL-1β in cell and mouse colitis models, highlighting a potential new pathway for IBD treatment research.

This study describes a new nanozyme approach that reduced inflammation and shifted the gut microbiome in mouse colitis models, suggesting a potential future strategy to boost probiotic therapy for IBD by targeting...

The study suggests that a physician-endorsed, librarian-developed information prescription may improve quality of life and reduce short-term relapse in people with IBD, a non-pharmacological approach that could be...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Procedures and surgery. The original article is from Endoscopy.

People with IBD who’ve had organ transplants (or are concerned about infection risk from systemic immunosuppression) may be interested because vedolizumab’s gut‑selective action could be preferable after kidney...

Diet is a modifiable factor that appears to change the gut microbiome and may affect symptoms and inflammation in both IBS and IBD; understanding which patterns help could guide practical dietary advice.

The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...

People with ulcerative colitis commonly experience depression; understanding whether the relationship is causal and which blood proteins might mediate it could help researchers develop biomarkers or new therapies...

Researchers are exploring plant-based formulas for inflammation beyond the gut. If the SGD effects translate to humans, it could point to new ways to prevent or treat liver injury that can accompany active UC by...

The paper identifies Candida albicans–reactive Th17 cells that travel between oral and gut mucosa and become more pathogenic in Crohn’s disease, suggesting a fungal–immune link that could matter for disease mechanisms...

A rectal 5-ASA gel that forms in place and sticks to the mucosa could reduce leakage and improve drug retention, potentially increasing effectiveness and patient comfort for people using topical therapies for ulcerative...

The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...

New targeted delivery approaches aim to concentrate therapy in the gut lining and inflamed areas, which could improve effectiveness and reduce systemic side effects for people with IBD.

This review collects preclinical evidence that a traditional Chinese medicine formula (Gegen Qinlian Decoction) may act on inflammation, the gut barrier, immunity, and microbiota — all relevant to ulcerative colitis and...

Macrophages and innate immune signaling are central to how gut inflammation starts and persists in IBD; better understanding these pathways could point to new treatment strategies for people whose disease doesn’t fully...

People with IBD may have overlapping genetic and cellular features with other autoimmune liver diseases like primary biliary cholangitis; understanding shared biology could eventually improve disease monitoring or point...

The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...

Cure8 found this source from Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, but the page could not be read reliably yet. It is tagged...

Cure8 found this source from Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, but the page could not be read reliably yet. It is tagged...

The study synthesizes many stool metagenomes to find consistent microbial species, functional pathways, and strain-level differences linked to IBD and to distinctions between Crohn’s disease and ulcerative...

If you have ulcerative colitis, the study suggests that TCM pattern labels (DCSR vs PXSY) align with measurable differences in inflammation and tissue damage, which could influence personalized symptom assessment or...

Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...

This study identifies a plant-derived polysaccharide (from the stem of Dendrobium huoshanense) that reduced inflammation and tissue injury in a mouse model of ulcerative colitis and points to GLP-1 signaling as a likely...

This study points to a specific immune pathway (IRF5 repressing S100A9) that controls suppressive granulocytic MDSCs in ulcerative colitis, suggesting a new target for therapies aimed at modulating harmful inflammation.